Whalesbook
📉 The Financial Deep Dive
Glenmark Pharmaceuticals has unveiled its Q3 FY26 financial results, showcasing a pronounced divergence between its consolidated and standalone business performance.
Consolidated Performance (Q3 FY26 vs Q3 FY25):
Consolidated revenue from operations demonstrated robust growth, rising by 15.1% year-on-year (YoY) to ₹39,006.15 million (₹39,006 Cr). Profit After Tax (PAT) also saw a significant uptick, increasing by 15.9% YoY to ₹4,032.28 million (₹4,032 Cr). This PAT growth was substantially influenced by a notable reduction in exceptional item charges compared to the corresponding prior year quarter.
For the nine-month period ended December 31, 2025 (9M FY26 vs 9M FY25), consolidated revenue surged by 30.5% YoY to ₹1,29,511.26 million (₹1,29,511 Cr). However, consolidated PAT growth was more subdued, clocking in at a modest 1.7% YoY to ₹10,606.33 million (₹10,606 Cr), indicating potential margin pressures or other factors affecting profitability over the nine-month period.
Standalone Performance (Q3 FY26 vs Q3 FY25):
In stark contrast, the company's standalone operations faced headwinds. Revenue from operations for the third quarter declined by 5.4% YoY to ₹23,282.31 million (₹23,282 Cr). Standalone PAT witnessed a sharp contraction of 32.1% YoY, falling to ₹2,820.66 million (₹2,821 Cr). This significant drop was partly attributed to an exceptional item charge of ₹1,770.73 million recognized due to the implementation of the New Labour Codes.
For the nine months ended December 31, 2025 (9M FY26 vs 9M FY25), standalone revenue saw a considerable decrease of 19.3% YoY, amounting to ₹57,266.59 million (₹57,267 Cr). The standalone nine-month period reported a net loss of ₹1,268.97 million (₹1,269 Cr), a dramatic reversal from a substantial profit of ₹14,625.90 million (₹14,626 Cr) in the prior year. This loss was heavily influenced by exceptional charges related to legal settlements and a significant tax credit recognized during the period.
Exceptional Items Analysis:
Exceptional items played a critical role in shaping the reported figures. In Q3 FY26, charges of ₹1,770.73 million (standalone) and ₹1,843.37 million (consolidated) were recognized, primarily related to the financial implications of the New Labour Codes. The prior year's consolidated quarter (Q3 FY25) bore a much higher exceptional charge of ₹18,926.85 million, which significantly depressed its PAT. This stark difference in prior year charges makes the current year's consolidated PAT growth appear robust by comparison. The company also continues to address costs associated with past US antitrust lawsuits settlements and restructuring.
🚩 Risks & Outlook
The primary risk for Glenmark investors lies in the pronounced divergence between the healthy consolidated performance and the deteriorating standalone operations. The standalone segment's revenue decline and its swing to a net loss in the nine-month period raise questions about its operational health and turnaround strategy.
Furthermore, the impact of exceptional items, while helping the consolidated year-on-year comparison, highlights underlying costs and potential future liabilities related to labour codes and legal settlements. Investors must scrutinize the sustainability of consolidated growth drivers and assess the company's ability to stabilize and recover its standalone business segments.
Management guidance on future performance, growth drivers, and strategies to mitigate standalone segment challenges is critical but was not provided in this release. The market will be watching for updates on operational improvements and resolution of exceptional items in upcoming quarters.